Abstracts

• Re-evaluation of response criteria in chronic lymphocytic leukemia and the significance of minimal residual disease

  Michael Hallek

  1-4

  https://doi.org/10.4081/hmr.v1i2.223

  298

  PDF: 866

  • PDF

• The role of minimal residual disease elimination in the outcome of chronic lymphocytic leukemia

  M. Hallek

  https://doi.org/10.4081/hmr.v1i2.229

  201

  PDF: 388

  • PDF

• Minimal residual disease following chemoimmunotherapy for patients with relapsed chronic lymphocytic leukemia

  Andreas Engert, Holger Schultz, Thomas Elter

  https://doi.org/10.4081/hmr.v1i2.228

  396

  Untitled: 0

  PDF: 284

  • PDF

• Minimal residual disease elimination by consolidation therapy with alemtuzumab

  Susan O’Brien

  https://doi.org/10.4081/hmr.v1i2.227

  200

  PDF: 292

  • PDF

• The role of alemtuzumab in the treatment of chronic lymphocytic leukemia (CLL) and the achievement of minimal residual disease negativity in relapsed/refractory CLL

  Peter Hillmen

  https://doi.org/10.4081/hmr.v1i2.226

  240

  PDF: 325

  • PDF

• Elimination of minimal residual disease in chronic lymphocytic leukemia using allogeneic stem cell transplantation

  Matthias Ritgen, Stephan Stilgenbauer, Andreas Humpe, Norbert Schmitz, Hartmut Döhner, Michael Kneba, Peter Dreger

  https://doi.org/10.4081/hmr.v1i2.225

  432

  Untitled: 0

  PDF: 275

  • PDF

• Evaluation of minimal residual disease in chronic lymphocytic leukemia

  Matthias Ritgen, Sebastian Böttcher, Peter Dreger, Michael Kneba

  https://doi.org/10.4081/hmr.v1i2.224

  348

  PDF: 1319

  • PDF